.jpg)
MOST POPULAR
- Rains over past three days extreme weather event: scientists
- Pedestrian questions
- Gujarat pollution board gets a makeover in efficiency 33
- Mirage of a river 5
- Dhari Devi idol goes missing
- Transition failure
- Monsoon arrives early; kills over 30 people in Uttarakhand
- Man-made reasons for Uttarakhand disaster
- The unseen invader
- Energy conservation building code for Andhra soon
- Environment ministry wants to restore night traffic through Bandipur tiger reserve 52
- A green facade 45
- Diesel: when bad policy makes for toxic hell 38
- Gujarat pollution board gets a makeover in efficiency 33
- What’s good insulation? 30
- How vulnerable are India's nuclear power plants to disaster 28
- Grand distraction called river interlinking 28
- Eat at your own risk 27
- Green energy takes toll on green cover 26
- Temporary solution, permanent jam 25
FOLLOW US ON
Nexavar
Activists demand compulsory licence for another life-saving cancer drug
@singh_jyotsna Issue Date: Mar 8, 2013
Encouraged by the recent decision of India's Intellectual Property Appellate Board (IPAB) to uphold the compulsory licence granted to generic drug manufacturer Natco for a cancer-drug, an advocacy group has demanded grant of licence for another cancer drug on occasion of International Woemn's Day on Friday. Members of the Campaign for Affordable Trastuzumab called on the commerce minister to grant similar licence to Trastuzumab, a life-saving drug for women with HER2+ breast cancer.
Will appellate body uphold grant of compulsory licence to cancer drug?
Issue Date: Jan 21, 2013
A patent triumph of public interest
Issue Date: Dec 15, 2012
Fresh winds are wafting changes in the stuffy world of pharmaceutical patents. Countries in Asia, Africa and Latin America—there are not too many just now—are enshrining flexibilities in their patent laws to ensure that public interest remains in the legal framework of the patent regime.
The NATCO CL fallout
Issue Date: Apr 30, 2012
No medicine can be cheap enough when one is fighting fatal diseases, specially the emperor of maladies. So there was much to shout about when Patent Controller P H Kurian granted Natco Pharma of Hyderabad a compulsory licence (CL) last month to make a generic version of Bayer Corporation’s sorefanib tosylate.
Indian company gets licence to manufacture and sell patented cancer drug
Issue Date: Mar 12, 2012
In a landmark judgment for cancer patients, Indian patent office has allowed generic drug manufacturer Natco Pharma Ltd to make and sell an anti-cancer drug Nexavar patented by Bayer Healthcare of Germany. This is the first ever compulsory license issued to a generic drug company in India to legally manufacture a drug while the patent is still operational.
